




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Saric, N., Selby, M., Ramaswamy, V., Kool, M., Stockinger, B., Hogstrand, J. L. C., ... Basson, M. A. (2020). The
AHR pathway represses TGF-SMAD3 signalling and has a potent tumour suppressive role in SHH
medulloblastoma. Scientific Reports, 10(1), [148]. https://doi.org/10.1038/s41598-019-56876-z
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Apr. 2020
1Scientific RepoRtS |          (2020) 10:148  | https://doi.org/10.1038/s41598-019-56876-z
www.nature.com/scientificreports
the AHR pathway represses tGfβ-
SMAD3 signalling and has a potent 
tumour suppressive role in SHH 
medulloblastoma
Nemanja Sarić1, Matthew Selby2, Vijay Ramaswamy  3,4, Marcel Kool5, Brigitta Stockinger6, 
Christer Hogstrand  7, Daniel Williamson2, Silvia Marino8, Michael D. taylor3,4, 
Steven C. clifford2 & M. Albert Basson1,9*
Sonic Hedgehog (SHH) medulloblastomas are brain tumours that arise in the posterior fossa. Cancer-
propagating cells (CPCs) provide a reservoir of cells capable of tumour regeneration and relapse 
post-treatment. Understanding and targeting the mechanisms by which CPCs are maintained and 
expanded in SHH medulloblastoma could present novel therapeutic opportunities. We identified the 
aryl hydrocarbon receptor (AHR) pathway as a potent tumour suppressor in a SHH medulloblastoma 
mouse model. Ahr-deficient tumours and CPCs grown in vitro, showed elevated activation of the 
tGfβ mediator, SMAD3. Pharmacological inhibition of the TGFβ/SMAD3 signalling axis was sufficient 
to inhibit the proliferation and promote the differentiation of Ahr-deficient CPCs. Human SHH 
medulloblastomas with high expression of the AHR repressor (AHRR) exhibited a significantly worse 
prognosis compared to AHRRlow tumours in two independent patient cohorts. Together, these findings 
suggest that reduced AHR pathway activity promotes SHH medulloblastoma progression, consistent 
with a tumour suppressive role for AHR. We propose that TGFβ/SMAD3 inhibition may represent an 
actionable therapeutic approach for a subset of aggressive SHH medulloblastomas characterised by 
reduced AHR pathway activity.
Medulloblastoma represents one of the most common forms of paediatric, malignant brain tumours accounting 
for around 20% of all paediatric tumours of the CNS1. Typical treatment consists of a combination of chemother-
apy, surgical resection and neuraxis irradiation, with a cure rate of approximately 70–75% in children ≥3 years 
of age2. However, survivors of medulloblastoma are left with a host of long-term adverse sequelae, including cog-
nitive deficits, problems with neuroendocrine function and fertility3,4. These drawbacks to traditional treatment 
options necessitate more effective patient stratification strategies based on biomarkers that predict outcome and 
identify specific molecular medulloblastoma subtypes for personalized, targeted therapies.
Efforts to dissect the molecular underpinnings of medulloblastoma have identified four main subgroups - WNT, 
Sonic hedgehog (SHH), Group 3 and Group 4 - with distinct transcriptional, DNA methylation and mutational 
profiles, and different clinical characteristics and outcomes5–7. These subgroups are associated with different 
cells of origin8. SHH tumours originate from cerebellar granule cell progenitors (GCPs), and display excessive 
activation of the SHH signalling pathway9. The prognosis of SHH subgroup medulloblastomas is mixed, with 
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some patients doing well and others not, suggesting significant heterogeneity within this subgroup7. Indeed, 
recent work has identified SHH medulloblastoma subtypes with specific molecular characteristics and associ-
ated clinical features5,6. Independent efforts showed that SHH MBs could be subdivided depending on age and 
molecular signature. Among these, infant (<3.0–4.0 years at diagnosis) and non-infant SHH subgroups are con-
sistently observed, alongside a subgroup of non-infant tumours associated with a particularly poor prognosis, 
characterized by amplifications of MYCN and GLI2 and loss of function mutations in TP535,6. These molecular 
signatures have previously been linked to medulloblastomas with metastasis and high rates of post-treatment 
relapse6,10,11. Non-infant SHH tumours without these features are associated with better outcomes (>80% 5-year 
progression-free survival5).
The Ahr gene, encoding the aryl hydrocarbon receptor, has been studied extensively in the context of hepa-
tocarcinoma, immune cell development and toxicology12–14, where this gene appears to have context-specific 
roles. In hepatocarcinoma, Ahr promotes cell proliferation and tumourigenesis12, while it has multiple roles in the 
immune system15. Intriguingly, activation of the AHR pathway by endogenous ligands has been shown to pro-
mote brain cancers by the anti-tumour immune response16, also suggestive of context-dependent, multi-faceted 
roles for this pathway in cancer biology. AHR is a bHLH (basic helix-loop-helix) transcription factor which 
acts as a receptor for endogenous tryptophan metabolites and xenobiotics such as TCDD17. Upon ligand bind-
ing, AHR translocates to the nucleus, where it forms a complex with formation of a heterodimer with ARNT 
(Aryl hydrocarbon Receptor Nuclear Translocator). AHR-ARNT heterodimers are recruited to Dioxin Response 
Elements (DRE) in the genome to regulate gene transcription18. An AHR Repressor (AHRR) protein can also 
dimerise with ARNT to competitively interfere with AHR-ARNT complex formation and inhibit AHR-regulated 
gene expression19.
Sox2+ cancer propagating cells (CPCs), capable of driving tumour initiation and exhibiting enhanced resist-
ance to cytostatic therapy have been identified in SHH medulloblastoma mouse models20,21. Lineage tracing 
experiments of these cells demonstrated their capacity for tumour regeneration following anti-mitotic chemo-
therapy, suggesting these cells are responsible for tumour relapse20. However, the mechanisms governing CPC 
formation and maintenance in SHH medulloblastomas remain to be fully elucidated. AHR function has been 
linked to CPC and haematopoietic stem cell maintenance22,23. In a recent study, AHR was shown to regulate the 
balance between quiescence and proliferation in hematopoietic stem cells, with these stem cells becoming less 
quiescent and more proliferative in Ahr-deficient animals23.
Previous studies have implicated AHR in cerebellar development and medulloblastoma cell prolif-
eration. Ahr deletion in primary cerebellar GCPs24 or AHR knock-down in a SHH-associated medul-
loblastoma cell line25 resulted in proliferative deficits. To determine if AHR has a direct role in SHH 
medulloblastoma in vivo, we conditionally deleted the Ahr gene in mouse cerebellar GCPs, either alone or in 
combination with medulloblastoma-initiating Ptch1 gene deletion. Our analyses of these mice revealed a striking 
tumour-suppressive role for AHR in mouse SHH medulloblastoma development. We identify a specific role for 
AHR in regulating the TGFβ-SMAD3 signalling axis in CPCs from these tumours and identify a new role for 
TGFβ-SMAD3 activity in medulloblastoma CPC differentiation. Examination of the expression of AHR pathway 
genes in human medulloblastoma cohorts support an important role for the AHR pathway in SHH medulloblas-
toma biology.
Results
AHR modulates primary mouse GCP proliferation and differentiation by repressing TGFβ/
SMAD3 signalling. To investigate the role of the AHR pathway in neural progenitor fate in the developing 
cerebellum, we conditionally deleted the Ahr gene from Math1+ GCPs during cerebellar development. In agree-
ment with a previous report24, we observed reduced GCP proliferation and enhanced cell cycle exit (as measured 
by cell Q fraction) (Fig. S1a) of GCPs in Ahr conditional knockout Math1cre; Ahrf/f (Ahr cKO) cerebella, com-
pared to control Ahrf/f cerebella (Fig. S1b,c). The phenotype was particularly prominent in anterior lobules I/II, 
III, V and VI (Fig. S1d,e). This effect was not observed in the posterior lobules IX/X, which is attributable to lack 
of Cre activity within these lobules, as described previously26.
We confirmed that this proliferative deficit was retained in vitro. Ahr-deficient, primary GCPs isolated from 
P7 Ahr cKO mice proliferated less compared to control GCPs (Fig. 1a,b). Furthermore, we found that more 
Ahr-deficient GCPs commenced differentiation as evidenced by expression of the definitive differentiation marker 
Neurod1 after a 24 hour culture period, compared to controls (Fig. 1a,c). A substantial fraction of GCPs displayed 
positivity for both Ki67 and Neurod1 (Fig. 1a), which can be expected to occur at 24 hours as cells are transition-
ing from a proliferative to a terminally differentiated state. To determine whether Ahr-deficient cells matured 
faster, primary GCPs were cultured in the absence of exogenous Sonic hedgehog (SHH) for six days in vitro  
and neurite length measured as an indicator of granule cell differentiation27. Map2 was used as a marker for neu-
rites due to its importance in stabilizing microtubule activity in mature neurons28. Ahr-deficient GCPs displayed 
>2-fold increase in neurite length on average compared to controls (Fig. 1d,e), confirming a role for Ahr in sup-
pressing GCP differentiation and maturation.
To identify molecular pathways that were altered in Ahr-deficient cells, we performed immunoblots of lysates 
from purified GCPs to detect activated signalling mediators. For instance, as AHR has been shown to regulate 
the TGFβ-SMAD signalling pathway in several other contexts29, including brain tumours30, we assayed for the 
activated, phosphorylated (S423 and S425) form of SMAD3, an intracellular mediator of TGFβ receptor acti-
vation31. P-SMAD3 levels were elevated several-fold in Ahr cKO GCPs compared to control GCPs (Fig. 2a,b). 
In comparison, neither P-SMAD2 levels, nor the total amount of SMAD2 and SMAD3 proteins were altered in 
these cells (Fig. 2a). To determine whether SMAD3 hyperactivation was responsible for the altered phenotype of 
Ahr-deficient GCPs, primary GCPs from control and Ahr conditional mutant mice were cultured in vitro in the 
presence of exogenous SHH, with or without the selective SMAD3 inhibitor SIS332. After 24 hours in culture, the 
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Figure 1. Ahr regulates the balance between proliferation and differentiation in GCPs. (a) Isolated P7 GCPs 
were cultured for 24 hours in the presence of exogenous SHH. Each cerebellum was processed independently 
(without pooling) from 3 control and 3 cKO littermates and the experiment repeated three times on separate 
occasions with independent litters. The data shown is the average of the three experiments with 9 WT 
and 9 cKO cerebella in total. Panels show immunostaining for Ki67 (green), Neurod1 (red) and Hoechst 
counterstained nuclei (blue). Merged panels show composite images. White arrows indicate Ki67+ cells. 
(b) Quantification of %Ki67 positive cells from a. (c) Quantification of %Neurod1 positive cells from a. (d) 
Isolated P7 GCPs were seeded in 6 well plates and allowed to differentiate in the absence of SHH, before 
immunocytochemical staining was performed for Map2 (green), followed by neurite tracing and quantification 
after 6 days in vitro (6 DIV). White arrows indicate neurites extending from granule neuron soma. (e) 
Quantification of neurite length (um). Data in panels b, c and e were analyzed by Student’s t test (p < 0.001 
(***), p < 0.01 (**), p < 0.05 (*)). Bars represent mean values +/− SEM. Scale bars: 10 um (a,d).
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fraction of proliferating and differentiating cells was quantified after immunostaining with antibodies to Ki67 and 
Neurod1, respectively. SIS3 treatment had no effect on the proliferation or differentiation of control GCPs in cul-
ture, suggesting that TGFβ-SMAD3 signalling is not an essential regulator of the proliferation or differentiation 
of these cells. However, the proliferative deficit of Ahr-deficient cells was fully rescued by SIS3 treatment, as was 
the tendency of these cells to differentiate (Fig. 2c,d). SIS3 treatment did not impact total GCP cell numbers over 
the course of 24 hours (Fig. S4a).
Together, these findings identify a role for AHR in keeping SMAD3 activation in check during normal GCP 
development. We conclude that SMAD3 hyperactivation is at least in part responsible for the proliferative deficit 
and enhanced differentiation of Ahr-deficient GCPs.
AHR supresses tumour progression in a SHH medulloblastoma mouse model. Cerebellar GCPs 
have been identified as the cell of origin for SHH medulloblastoma33,34. In mice, the conditional deletion of 
Ptch1, encoding the SHH receptor Patched1, which functions as an inhibitor of the SHH pathway, results in 
hyper-proliferation of GCPs, their rapid transformation and lethal medulloblastoma development in 100% of ani-
mals35. To determine whether Ahr has a role in SHH medulloblastoma, we deleted Ahr in these cells together with 
Ptch1. As previously reported35, 100% of Math1cre; Ptch1f/f (Ptch1 cKO) animals succumbed to medulloblastoma 
within 3 months of age, with a median survival of 63.5 days (Fig. 3a). By comparison, all Math1cre; Ptch1f/f; Ahrf/f 
Figure 2. Loss of Ahr promotes GCP cycle arrest through enhanced activation of the TGF-β/SMAD3 axis. 
(a) Western blots of total cell lysates of isolated P7 GCPs from control and Ahr cKO cerebella with antibodies 
specific to phosphorylated S423/S425 residues of SMAD3 and phosphorylated S465/467 residues of SMAD2 
proteins as well as antibodies against total SMAD2/3 and GAPDH (loading controls). Molecular weight 
markers are indicated on the left. (b) Quantification of band optic density for phosphorylated SMAD3, relative 
to total SMAD2/3, normalized to GAPDH levels. (c) Quantification of %Ki67 positive cells in non-treated (−) 
and 1 uM SIS3 (+SIS3) treated cultures. (d) Quantification of %Neurod1 positive cells. Data shown in (c,d) 
is representative of GCPs (on average 100 cells counted from 4 different fields of view from triplicate wells) 
isolated from 3 animals of each genotype, cultured for 24 hours in triplicate. Data was analyzed by Student’s t 
test (p < 0.001 (***), p < 0.01 (**), p < 0.05 (*)). Bars represent mean values +/− SEM.
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(Ptch1 cKO Ahr cKO) animals died within 40 days of age, with a median survival of 33 days (Fig. 3a). The shorter 
survival time of animals with Ahr-deficient GCPs was highly significant (p < 0.0001, log-rank test). All animals 
presented with large medulloblastoma tumours with characteristic classic histology (Fig. 3b).
Ahr-deficient medulloblastoma tumours have an undifferentiated phenotype. To character-
ize the salient features that distinguish Ahr-deficient from control tumours, we compared cell proliferation and 
differentiation. Overall, cellular proliferation was slightly, but significantly increased in Ahr-deficient tumours 
compared to control tumours (Fig. 3c,d). A comparison of control and Ahr-deficient tumours for steady-state 
levels of neuronal differentiation markers did not reveal any obvious difference in the levels of differentiation in 
Ahr-deficient tumours (Fig. 3e).
Ahr controls cancer-propagating cell proliferation and differentiation via TGFβ-SMAD3 inhibition. 
Next, we asked whether AHR also inhibited SMAD3 activation in SHH medulloblastoma. Immunoblot analysis 
of tumour lysates found elevated levels of P-SMAD3 in Ahr-deficient samples, compared to controls (Fig. 4a,b). 
Levels of total SMAD2/3 protein were also increased in Ahr cKO tumours (Fig. S3c,d). Immunostaining of medul-
loblastoma tissue revealed a salt and pepper distribution of P-SMAD3 positive cells in the tissue, suggesting that 
only a subset of cells in Ahr cKO tumours responded to TGFβ signals at a given time point (Fig. 4c). When com-
paring P-SMAD3 immunostaining between control and Ahr cKO medulloblastomas, we found that the number 
Figure 3. Ahr deletion in GCPs exacerbates tumorigenesis in a mouse model of SHH medulloblastoma. (a) 
Kaplan-Meier survival curves for Math1cre; Ptch1f/f (Ptch1 cKO; n = 19) and Math1cre; Ahrf/f; Ptch1f/f (Ptch1 
cKO; Ahr cKO; n = 15) mice. (b) Representative haematoxylin/eosin (H&E) staining showing classic histology 
in both Ptch1 cKO and Ptch1 cKO; Ahr cKO medulloblastomas. (c) Immunohistochemical staining for mitotic 
marker pH3B (phosphorylated histone H3B) in brown. (d) Quantification of pH3B+ cells/mm2 of tumour 
(4 non-adjacent sections from 3 tumours of each genotype). (e) Immunostaining for neural differentiation 
markers synaptophysin, Map2 and NeuN (brown). Statistical comparison of survival curves in panel (a) was 
performed by log-rank test (p < 0.001 (***)). Data shown is of a single tumor assessed from each animal (n = 3 
WT and 3 cKOs), as each animal presented with a single large tumour. Proliferation data in panel (d) was 
analyzed by Student’s t test (p < 0.05 (*)). Bars represent mean values +/− SEM. Scale bars: 50 um.
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of cells with detectable P-SMAD3, as well as the intensity of P-SMAD3 staining in these cells, were increased in 
Ahr-deficient tumour tissue (Fig. 4d).
Given previous studies linking Ahr function with maintenance of the cancer-propagating cell (CPC) com-
partment36,37 and the evidence supporting a role for Sox2+ CPCs in promoting SHH medulloblastoma aggres-
siveness20,21, we decided to investigate whether the elevated SMAD3 activity in Ahr-deficient medulloblastoma 
modulated important CPC properties. To achieve this, we established primary cultures of CPCs from end stage 
medulloblastomas and maintained these cells in serum-free stem cell medium supplemented with growth factors, 
as described previously38 (Fig. 5a). As expected, the majority (70–80%) of medulloblastoma CPCs were positive 
for the neural stem cell marker Sox2 and TGFβ inhibitor treatments had no effect on the proportion of Sox2 
expressing cells (Fig. S2a), indicating that Sox2+ cell identity or Sox2 expression were not dependent on TGFβ 
signalling. Immunostaining of these cells revealed that all Ahr-deficient medulloblastoma CPCs were strongly 
positive for p-SMAD3, compared to control culture that did not display SMAD3 activation (Fig. 5b). This finding 
suggested that the AHR pathway suppressed TGFβ-SMAD3 signalling in Sox2+ cells.
In agreement with observations in tumour sections (see Fig. 3d), Ahr-deficient cultures contained significantly 
higher numbers of proliferating cells compared to controls (Fig. 5c,d). Inclusion of the SMAD3 phosphoryl-
ation inhibitor SIS332 in these proliferating cultures reduced levels of cycling to near control levels (Fig. 5c,d). 
Quantification of the proportion of cycling (Ki67+) Sox2+ CPCs revealed the same trend (Fig. 5e). These data 
implicating TFGβ/SMAD3 signalling in medulloblastoma CPC proliferation were corroborated by treating the 
cells with the selective TGF-β receptor I inhibitor SB-431542 (SB43)39 (Fig. 5d,e). Treatment of Ahr-deficient 
Figure 4. SMAD3 phosphorylation is increased in Ahr-deficient SHH medulloblastomas. (a) Western blots 
of total cell lysates of isolated end stage medulloblastoma tissue with antibodies specific to phosphorylated 
S423/S425 residues of SMAD3 (P-SMAD3), total SMAD2/3 and GAPDH proteins. (b) Quantification of band 
optic density for phosphorylated SMAD3 relative to SMAD2/3 levels, normalized to GAPDH levels. Data is 
representative of 3 animals/genotype. (c) Immunohistochemical staining of end stage tumour sections with 
P-SMAD3 antibody (in brown) with methyl green counterstaining nuclei. (d) Quantification of P-SMAD3+ 
cells/mm2 of tumour tissue (4 non-adjacent sections from 3 tumours of each genotype). Data was analyzed by 
Student’s t test (p < 0.001 (***)). Bars represent mean values +/− SEM. Scale bars: 100 um.
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CPCs with both SIS3 and SB43 inhibitors led to a significant reduction in cell numbers (~25% with SIS3 and 
~35% with SB43), suggesting that TFGβ/SMAD3 signalling may function by promoting CPC survival. Together, 
these findings implicated the TGF-β/SMAD3 pathway in mediating the effect of AHR signalling on proliferation 
and cell survival of medulloblastoma CPCs.
To ask whether Ahr deletion prevented medulloblastoma CPC differentiation via TGFβ-SMAD3 signalling, 
cells were transferred to a culture medium that promotes the differentiation of these cells38. Under these dif-
ferentiation conditions, control cells completely lost expression of Sox2 with 7 days, while approximately 60% 
of Ahr-deficient medulloblastoma CPCs retained high levels of Sox2 expression, indicative of a retention of an 
Figure 5. Ahr suppresses SHH MB CPC proliferation by repressing SMAD3 activation. (a) Procedure involved 
in isolation and maintenance of MB CPCs38. (b) Immunocytochemical staining of proliferating MB CPC 
cultures for phosphorylated SMAD3 (green) with Hoechst counterstained nuclei (blue). (c) The same cultures 
were treated for 24 hours with or without TGFβ pathway inhibitors and stained for Ki67 (green), Sox2 (red) and 
Hoechst (blue). (d) Quantification of %Ki67+ cells in non-treated (−), 500 nM SB43 (+SB43) and 1uM SIS3 
(+SIS3) treated cells. (e) Quantification of %Ki67+; Sox2+ (double positive) cells in each culture condition. (f) 
Quantification of total cell number/field of view based on Hoechst staining. On average 100 cells were counted 
from 4 different fields of view from triplicate wells of each condition. Data shown is representative of CPCs 
isolated from 2 animals/genotype with experiments performed in triplicate for each. Data was analyzed by 
Student’s t test (p < 0.01 (**), p < 0.05 (*)). Bars represent mean values +/− SEM. Scale bars: 10 um (b,c).
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undifferentiated phenotype (Fig. 6b,d). Control Ptch1 cKO CSC cultures maintained under these differentiation 
conditions were still characterised by low levels of SMAD3 activity, compared to Ptch1 cKO; Ahr cKO cells that 
had high levels of nuclear P-SMAD3 (Fig. 6a).
Treatment of Ahr cKO cultures with either TGFβ/SMAD inhibitors (SB43 and SIS3) over 7 days significantly 
reduced the proportion of Sox2+ cells by 30–40% (Fig. 6d). Inhibitor treatments had no effect on Sox2+ cells 
in control cultures. To confirm and compare levels of differentiation, both control and Ahr cKO CPC cultures 
were stained for TuJ1/βIII tubulin, a marker of immature neuron differentiation38. After 7 days of differentiation, 
nearly 80% of control Ptch1 cKO CPCs were positive for TuJ1, while only 5–10% of Ptch1 cKO; Ahr cKO CPCs 
were positive for this marker (Fig. 6c,e). TGFβ inhibition increased TuJ1 expression in Ahr cKO cultures, while 
having no effect on control CPC differentiation (Fig. 6c,e). The rescue effect on Ahr cKO cultures was partial, 
suggesting involvement of other pathways beside TGFβ/SMAD3 in promoting resistance to differentiation in 
Ahr cKO CPCs.
Taken together, these studies suggested that Ahr deletion in SHH medulloblastoma promoted CPC fate 
via induction of TGFβ/SMAD3 signalling. Correspondingly, TGFβ/SMAD3 inhibition promoted CPC 
differentiation.
SHH medulloblastoma patients with high levels of AHRR expression show reduced survival. 
To determine if our findings of a tumour-suppressive role for the AHR pathway may have direct clinical rele-
vance, we examined the expression of AHR in a cohort of human medulloblastomas, profiled by the Clifford 
group, with the following subgroup distribution: WNT (n = 28), SHH (n = 58), Grp 3 (n = 59), Grp 4 (n = 95). 
AHR gene expression was significantly higher in the WNT subgroup, with no difference between other subgroups 
(Fig. 7a). Furthermore, AHR expression levels did not correlate with patient survival in any subgroup (data not 
shown). Intriguingly, we found that the expression of the AHRR gene, which encodes an AHR Repressor protein, 
was elevated specifically in the SHH subgroup (Fig. 7b). When examining the association between AHRR expres-
sion in SHH tumours and patient survival, we found a statistically significant reduction in patient survival in 
medulloblastomas with high (>median) AHRR expression (Fig. 7c). This relationship between AHRR expression 
and survival was specific to the SHH subgroup with no associations found in other subgroups (data not shown). 
These findings are consistent with a model whereby a reduction of the AHR pathway, either via reducing Ahr 
expression (as in our mouse model), or increased AHRR expression in human tumours, is associated with more 
aggressive SHH medulloblastoma tumours and reduced patient survival.
Finally, we asked if we could replicate our human medulloblastoma findings in an independent, larger patient 
cohort. An analysis of 172 SHH tumours from the Taylor group in Toronto, confirmed both the increased expres-
sion of AHRR in SHH tumours, compared to other subgroups (Fig. 7d), as well as reduced survival of patients 
with high AHRR expression (Fig. 7e). The same AHRR expression profile was observed across medulloblastoma 
subgroups in a third, independent cohort profiled by the Kool group in Heidelberg (Fig. 7f), however no corre-
lation between AHRR expression levels and survival was observed in this particular cohort of SHH medulloblas-
tomas (Fig. 7g).
Discussion
Here we identified a critical role for Ahr in preventing activation of the TGFβ mediator SMAD3, both in pri-
mary cerebellar GCPs and GCP-derived SHH meduloblastoma. We further found that CPCs derived from 
Ahr-deficient tumours exhibited very high levels of P-SMAD3 compared to tumours with intact Ahr. Ahr deletion 
in GCPs together with the cancer-initiating Ptch1 gene deletions dramatically reduced survival, identifying a 
potent tumour-suppressive role for Ahr. CPCs from these Ahr-deficient tumours were refractory to differentia-
tion in vitro. Most importantly, pharmacological inhibition of the TGFβ-SMAD3 pathway was sufficient to drive 
Ahr-deficient CPCs towards differentiation, identifying this pathway as a potentially viable therapeutic target for 
aggressive medulloblastoma subtypes with reduced AHR pathway activity and elevated TGFβ-SMAD3 signalling. 
Transcriptomic analyses of human SHH medulloblastomas indeed identified a substantial subset of SHH primary 
tumours with high AHRR expression and poor prognosis in two independent patient cohorts. As these aggressive 
SHH medulloblastoma subtypes are highly resistant to conventional therapies, future studies to fully characterise 
these AHRRhigh tumours, establish to what extent they resemble Ahr-deficient SHH tumours in the mouse, and 
explore the potential of TGFβ-SMAD3 pathway inhibition will be important.
Several mechanistic questions remain to be answered. Exactly how Ahr deletion leads to specific activation of 
SMAD3, and not SMAD2 is not known. This apparently exquisite specificity argues against a general induction 
of TGFβ ligands or membrane receptors, which would be expected to activate both SMAD2 and SMAD3. The 
increase in total SMAD2/3 protein levels suggests Ahr might also function by either suppressing SMAD2/3 tran-
scription in the tumour context or promoting SMAD2/3 proteolytic turnover.
Our findings further support the idea that the role of the AHR pathway is highly context-specific. In primary 
GCPs, Ahr deletion leads to reduced proliferation and enhanced differentiation, while in SHH medulloblastomas 
derived from these cells, Ahr deletion has the opposite effect. These observations are particularly important in the 
light of a previous study showing that Ahr knockdown in the SHH-like medulloblastoma cell line DAOY resulted 
in reduced cell proliferation25.
It should be noted that other genes in the AHR pathway have been implicated in medulloblastoma. In par-
ticular, the Arnt (Aryl hydrocarbon receptor nuclear translocator) gene, which encodes an AHR interacting pro-
tein necessary for its function, can promote leptomeningeal metastatic dissemination when overexpressed in 
SHH medulloblastomas in the mouse40. Whether these effects are as a result of modulation of the AHR pathway 
remains to be determined.
It is intriguing to consider our observations in SHH medulloblastoma CPCs in the context of other brain 
tumours. Gramatzki et al. have shown that AHR inhibition in glioma cells also resulted in upregulation of the 
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Figure 6. Ahr-deficient MB CPCs resist differentiation partly through SMAD3 activation. (a) 
Immunocytochemical staining of 7 DIV (day in vitro) differentiation cultures for P-SMAD3 (green) and 
Hoechst (blue). Note increased P-SMAD3 signal intensity in Ahr cKO cultures. (b) Staining of Ptch1 cKO and 
Ptch1 cKO; Ahr cKO cultures with/without 1uM SIS3 for Sox2 (red). (c) Staining of the same cultures for TuJ1/
βIII tubulin (green). (d) Quantification of %Sox2+ cells in all culture conditions. (e) Quantification of %TuJ1+ 
cells in all culture conditions. On average 100 cells were counted from 4 different fields of view from triplicate 
wells of each condition. Note increased number of Sox2+ and reduced number of TuJ1+ cells in Ahr cKO CPCs 
and partial rescue with SIS3 treatment. Data shown is representative of CPCs isolated from 2 animals/genotype 
performed in triplicates. Data was statistically analyzed by Student’s t test (p < 0.001 (***), p < 0.01 (**), 
p < 0.05 (*)). Bars represent mean values +/− SEM. Scale bars: 10 um (a–c).
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Figure 7. Significantly reduced survival of patients with SHH MB expressing high levels of AHR repressor 
(AHRR). (a) AHR gene expression comparison across different medulloblastoma subgroups (WNT (n = 28), 
SHH (n = 58), Grp 3 (n = 59), Grp 4 (n = 95)) from the Clifford cohort. Note significant difference in WNT 
subgroup. (b) AHRR gene expression comparison across different medulloblastoma subgroups. Note significant 
difference in SHH subgroup. (c) Kaplan-Meier survival curves from Clifford group patient dataset showing 
survival rate comparison between SHH MB patients with high and low expression of AHRR for the 56 SHH 
patients for whom follow-up data was available. (d) AHRR gene expression comparison across different 
medulloblastoma subgroups (WNT (n = 70), SHH (n = 223), Grp 3 (n = 144), Grp 4 (n = 326)) from the 
SickKids cohort6. Note significant difference in SHH subgroup. (e) Kaplan-Meier survival curves from Taylor 
group patient dataset showing survival rate comparison between SHH MB patients with AHRR expression 
below or above median levels. Note similar trend with Clifford dataset of reduced survival probability with 
heightened AHRR expression. (f) AHRR gene expression comparison across different medulloblastoma 
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TGFβ-SMAD pathway30. Elevated TFGβ-SMAD signalling promotes glioma stem cell self-renewal and is asso-
ciated with more aggressive gliomas and poorer survival41,42. Together, these findings imply some conservation 
in the role of AHR in repressing the TGFβ-SMAD pathway in brain tumour stem cells and suggest the possi-
bility that inactivation or repression of this pathway may represent a mechanism whereby tumour cells retain a 
stem-like character and become resistant to differentiation. This study did not assess the effects of TGFβ-SMAD 
pathway modulation on apoptosis, however a significant decrease in Ahr cKO CPC number observed with SB43 
and SIS3 treatment suggests that enhanced CPC survival may be an important mechanism of increased tumori-
genicity in Ahr-deficient SHH medulloblastoma.
The role of the TGFβ-SMAD pathway specifically in medulloblastoma remains unclear. The present study 
links hyper-activation of this pathway in SHH medulloblastoma with resistance to differentiation and poor prog-
nosis. This finding is in disagreement with Aref et al. who suggested that nuclear SMAD3 localisation as a proxy 
read-out of SMAD3 activation in SHH medulloblastoma samples correlated with good prognosis43. This study 
only assessed SHH medulloblastomas from 35 patients and using nuclear localisation of SMAD3 as a read-out of 
pathway activation may not be ideal. Clearly, a larger study to assess P-SMAD3 immunoreactivity will be impor-
tant. Interestingly, elevated TGFβ signalling has also been implicated as a driver of Group 3 medulloblastoma44, 
suggesting that this pathway may also play important roles in other medulloblastoma subtypes.
Our human transcriptomic analyses identified AHRR expression as a novel biomarker for aggressive SHH 
medulloblastoma in two of three independent cohorts investigated. Demographic differences and the mixed ther-
apies deployed within these retrospective cohorts may explain the lack of consistent observations in all three 
cohorts, and these encouraging initial findings now require prospective validation in clinical trials-based cohorts. 
Determining to what extent high AHRR expression in human SHH medulloblastoma is associated with elevated 
TGFβ-SMAD3 signalling will be an important next step to identify patients that may benefit from TGFβ-SMAD3 
inhibition and/or AHR agonist therapies.
Materials and Methods
Animals. Math1cre45, Ptch1 flox46, and Ahr flox47 mouse lines have been described and were genotyped by 
PCR using tail or ear DNA extracted using proteinase K digestion or the HotSHOT method48. PCR primers used 
are indicated in the table below. Ptch1 cKO mice were generated by crossing Math1cre and Ptch1f/f mice, followed 
by crosses of the resultant Math1cre; Ptch1f/+ with Ptch1f/f animals. Ahr cKO medulloblastoma mice were gener-
ated by crossing Math1cre and Ahrf/f; Ptch1f/f mice followed by crosses of the resulting Math1cre; Ahrf/+; Ptch1f/+ 
mice with Ahrf/f; Ptch1f/f animals. Mice were bred and maintained according to Home Office regulations in New 
Hunt’s House, Biological Services Unit, King’s College, London. For postnatal stages the day of birth was desig-
nated postnatal day 0 (P0). All mice on tumour watch were monitored closely for symptoms of medulloblastoma 
and were sacrificed upon discovery of symptoms such as hydrocephalus, weight loss and ataxic gait49. The institu-
tional Local Ethical Review Panel and the UK Home Office approved all experimental procedures (Project licence 
numbers: 70/7506 and P8DC5B496). All procedures were carried out by a personal licence holder.
Thermal cycles for Cre and Ptch1flox genotyping were as follows: 94 °C, 10 minutes; 40× (94 °C, 45 sec; 57 °C, 
45 sec; 72 °C, 60 sec); 72 °C, 7 minutes. Thermal cycles for Ahrflox genotyping were: 94 °C, 3 minutes; 35 × (94 °C, 
30 sec; 69 °C, 60 sec; 72 °C, 60 sec); 72 °C, 2 minutes.
Tissue processing and histology. Brains were dissected in ice cold PBS and fixed in 4% paraformaldehyde 
(PFA) at 4 °C. Samples were dehydrated, cleared and infiltrated with paraffin wax using a Leica ASP300 Tissue 
Processor, followed by sagittal embedding in paraffin. Paraffin tissue blocks were sectioned using a microtome 
(Leica RM2145). Serial sections were cut at 4–10 μm thickness and mounted onto glass slides (SuperfrostPlus®, 
VWRTM).
Immunohistochemistry. 3, 3′-diaminobenzidine (DAB) immunohistochemistry. Sections were deparaffin-
ised and rehydrated through a series of graded ethanols to PBS. Endogenous peroxidases were blocked in a solu-
tion containing 3% H2O2 (stock 30%) and 10% methanol in PBS for 15 minutes and were subsequently rinsed 
with dH2O. Sections were then heated in the microwave at full power in a 10 mM sodium citrate solution (pH 
6.0) (4 × 5 mins) to break methylene bridges associated with the fixation process and expose antigenic sites. After 
cooling for 20 minutes at room temperature, cells were then permeabilised using 0.2% PBSTx (Triton®X-100 in 
PBS) (1 × 10 minutes) and non-specific antibody binding was blocked by incubating slides in 10% goat serum in 
PBSTx for 1 hour at room temperature. Sections were then incubated with the primary antibody diluted in 5% 
goat serum in PBSTx overnight at 4 oC. The following day unbound antibody was removed using three 10 minute 
0.1% PBSTx washes and sections were then incubated in the appropriate biotinylated secondary antibody (1/200) 
subgroups (WNT (n = 53), SHH (n = 112), Grp 3 (n = 94), Grp 4 (n = 164)) from the Kool cohort. Note 
significant difference in SHH subgroup. (g) Kaplan-Meier survival curves from Kool group patient dataset 
showing survival rate comparison between SHH MB patients with AHRR expression below or above median 
levels. Data in a,b and d were statistically analyzed by an Anova test and data in c,e and g by log rank test.
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diluted in 5% goat serum in 0.1% PBSTx. After 1 hour at room temperature unbound secondary antibody was 
washed off using PBS (3 × 10 minutes). The signal was then amplified using the VECTASTAIN Avidin Biotin 
Complex (ABC) kit by incubating sections in a solution containing 1/200 dilutions of A and B in PBS for 1 hour 
at room temperature. Sections were then washed in PBS (3 × 10 minutes) and visualised with 0.03% 3, 3′- diami-
nobenzidine (DAB) substrate (stock 30% in Tris-HCl)/ 0.0003% hydrogen peroxide (stock 30%). After visualiza-
tion sections were then counterstained with Methyl Green (1 × 5 minutes), briefly washed under running water 
and then dehydrated in a series of ascending ethanols, cleared in xylene, mounted using DPX and imaged with a 
Nikon Eclipse 80i microscope.
Immunofluorescence. Paraffin sections. Sections were deparaffinised and rehydrated as above and 
washed with PBS (2 × 5 mins). Antigen retrieval was performed by heating sections in a solution of 10 mM 
sodium citrate (pH 6.0) for 4 × 5 minutes at full power in the microwave. Sections were then left to cool to room 
temperature for 20 minutes. Tissue was permeabilized in 0.2% PBSTx and blocked in 10% heat inactivated 
goat serum in PBSTx for 1 hour before incubating in primary antibody in 5% goat serum in PBSTx overnight 
at 4 oC. The following day, unbound antibody was removed using 3 × 10 minute PBS washes. Slides were incu-
bated with Alexa-Fluor-labelled secondary antibodies (1/200, Life technologies) in 5% goat serum in PBSTx. 
Unbound secondary antibody was then washed off with 3 × 10 minute PBS washes. The nuclear counterstain, 
4′-6-diamidino-2-phenylindole (Dapi) (1:5000, Invitrogen) was added to the final wash and slides were mounted 
using Citifluor (www.citifluor.com). Tumour histology for differentiation markers Synaptophysin, MAP2 and 
NeuN were performed on a Ventana Medical System Benchmark automated immunostainer as described50.
Fixed cells. Cells fixed on coverslips with 4% PFA were initially washed with 2 × 10 minute PBS washes. They 
were then permeabilized in 0.2% PBSTx and blocked in 10% heat inactivated goat serum in PBSTx for 1 hour 
before incubating in primary antibody in 5% goat serum in PBSTx overnight at 4oC. The following day, unbound 
antibody was removed using 3 × 10 minute PBS washes. Slides were incubated with Alexa-Fluor-labelled sec-
ondary antibodies (1/200, Life technologies) in 5% goat serum in PBSTx. Unbound secondary antibody was 
then washed off with 3 × 10 minute PBS washes. The nuclear counterstain, 4′-6-diamidino-2-phenylindole (Dapi) 
(1:5000, Invitrogen) was added to the final wash and slides were mounted using Citifluor (www.citifluor.com). 
Fluorescent images were captured using Nikon Eclipse 80i with Nikon Y-QT Hamamatsu C4742-95 camera.
Antibodies. Primary. Primary antibodies used were as follows: rabbit anti-GAPDH (1/2500, Abcam, 
ab9485), rabbit anti-phospho histone H3B (1/200, NEB, 9701S), rat anti-BrdU (1/50, Abcam, ab6326), mouse 
anti-BrdU (1/100, BD, 347580), mouse anti-NeuN (1/2000, Chemicon), mouse anti-Map2 (1/500, Chemicon), 
rabbit anti-Ki67 (1/1000, Abcam, ab15580), rabbit anti-P-SMAD2/3 (1/1000, NEB, D27F4), rabbit anti-SMAD2/3 
(1/1000, NEB, 3102S), mouse anti-Neurod1 (1/100, Abcam, ab60704), rabbit anti-synaptophysin (Pe-dilued, 
Zymed, 080130), rabbit anti-P-SMAD3 (1/100, Abcam, ab52903), rabbit anti-TuJ1 (1/500, Abcam, ab18207) and 
mouse anti-Sox2 (1/500, Abcam, ab79351).
Secondary. For western blots primary antibodies were detected using polyclonal goat anti-rabbit IgG horse 
radish peroxidase (HRP) conjugated secondary antibody (1/2000, Thermofisher, 65-6120). For DAB immuno-
histochemistry primary antibodies were detected using polyclonal goat anti-mouse IgG biotinylated secondary 
antibody (1/200, Dako, E0433), polyclonal goat anti- rabbit IgG biotinylated secondary antibody (1/200, Dako, 
E0432). For immunofluorescence primary antibodies were detected using Alexafluor-488 goat anti-rabbit IgG 
(Invitrogen, 1/200, A11034), Alexafluor-568 goat anti-mouse IgG (Invitrogen, 1/200, A21124), Alexafluor-488 
goat anti-mouse IgG (Invitrogen, 1/200, A11001), Alexafluor-568 goat anti-rabbit IgG (Invitrogen, 1/200, 
A11011) secondary antibodies.
Western blots. Purified GCPs were isolated from P7 cerebella and either whole cell protein or subcellular 
fractions were prepared by lysing in N-PER lysis buffer (Thermofisher) or subcellular fractionation buffers 
(Thermofisher) respectively, following the manufacturer’s instructions. All buffers contained protease inhibitors 
(PMSF, Pepstatin A, Leupeptin, Aprotinin; Roche) and a phosphatase inhibitor cocktail (Sigma). Protein loading 
samples were made by diluting samples in Laemmli buffer containing 10% β-mercaptoethanol, followed by boil-
ing at 95 °C for 5 minutes. Samples were loaded (10 µg total protein per lane) onto a Mini-PROTEAN pre-cast gel 
(Bio-Rad) and resolved using gel electrophoresis. Protein was transferred to a nitrocellulose membrane (Bio-Rad) 
which was then blocked in 5% non-fat milk powder (Bio-Rad) or 3% bovine serum albumin (BSA, Sigma) in TBS 
with 0.1% Tween-20 (TBST) for one hour at room temperature, followed by incubation with primary antibodies 
diluted in 3% BSA/TBST overnight at 4 °C. The next day the membranes were washed 3 × 10 mins in TBST, fol-
lowed by incubation in secondary antibodies diluted in 5% non-fat milk powder in TBST for one hour at room 
temperature. Membranes were subsequently washed again 3 × 10 minutes in TBST and HRP was detected with 
Clarity ECL reagent (Bio-Rad) and the membranes imaged using a Bio-Rad ChemiDoc system. Relative protein 
quantity was calculated using Bio-Rad ImageLab software.
Cerebellar GCP isolation. GCPs were isolated as described previously51. The cerebella from P7 control and 
Math1cre; Ahrf/f pups were dissected in ice-cold DPBS. The lobules that retain Ahr expression (IX + X) along with 
the flocculus and paraflocculus were removed. Each cerebellum was processed separately. Papain-I (100 U in 
10 ml DPBS) was dissolved in 10 ml of DPBS at 37 °C. Once dissolved, 200 μl of DNaseI (12,500 U/ml, Sigma) was 
added and the Papain-I enzyme was activated by adding L-Cysteine (2 mg/10 ml). After adjusting the pH to using 
2 N NaOH, cells were dissociated by incubating the cerebella in the Papain-I containing solution for 30 minutes 
at 37 °C followed by trituration in ovo solution (2 mg/ml ovomucoid, 125 U/ml DNaseI in DPBS). Dissociated 
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cells were then centrifuged for 10 minutes at 1000 rpm. The supernatant was then aspirated and the pellet sus-
pended in DPBS-BSA (DPBS containing 1% BSA). The suspension was then passed through a cell strainer before 
underlaying the solution containing the dissociated cells with 35% Percoll followed by 65% Percoll. Cells were 
then separated according to size by centrifugation (12 minutes, 2500 rpm). The layer constituting the interphase 
between the 35% and 65% Percoll layers, containing GCPs, was then removed and placed in a separate falcon tube 
containing 14 ml of DPBS-BSA. GCPs were counted using a haemocytometer, the solution containing GCPs was 
then centrifuged (10 minutes, 1400 rpm) and the supernatant aspirated.
Cell culture. Purified GCPs were cultured in Neurobasal media (Thermofisher) supplemented with B27 
(Thermofisher), exogenous SHH, glutamine (Thermofisher) and penicillin/streptomycin (Sigma). The SHH 
came from supernatant obtained from conditioned media from HEK293T cells transfected with pcDNA3.1 
ShhN plasmid. pcDNA3.1 ShhN was a kind gift from Philip Beachy (Addgene plasmid # 37680). Culture ves-
sels were pre-coated with poly-D-lysine (Sigma) before cell seeding. Media was changed every other day to 
maintain growth conditions. Omission of exogenous SHH promoted differentiation. CPCs were isolated from 
end-stage tumours as described in Fig. 5a. CPCs were cultured as described in38. Briefly, enriched CPCs were 
cultured in Neurobasal media supplemented with B27 (Thermofisher), N2 (Thermofisher), bFGF (Peprotech), 
EGF (Peprotech), glutamine (Thermofisher) and penicillin/streptomycin (Sigma) to maintain growth condi-
tions. Media was changed every other day in expanding cultures. Culture vessels were pre-coated with 0.1% gel-
atin (Sigma) before cell seeding. Upon switching the medium to 10% serum in DMEM (Thermofisher) the cells 
underwent differentiation. In experimental cultures SB-431542 (SB43) (Sigma) or SIS3 (Sigma) were added to 
some culture wells as part of a daily change of medium. SB43 functions as an inhibitor of the transforming growth 
factor-beta superfamily type I (TGFβRI) receptor39 while SIS3 is a specific inhibitor of SMAD3 phosphorylation 
and its interaction with SMAD432.
Quantitative analysis. Ki67+ and Neurod1+ cells quantified in Figs. 1b,c and 2c,d were counted from four 
different fields of view/quadrants (top to bottom, left to right) from triplicate wells (of 24 well plates) of each 
condition. Hoechst counterstained cells were counted alongside and the final % positivity calculated and aver-
aged for each condition. The Hoechst staining quantification is from the same fields with filter change. Neurites 
were traced using the Simple Neurite Tracer plugin in ImageJ and the path lengths of traced neurites from each 
cell in the field of view were converted to a micron scale before calculating the mean length. The starting point 
of the neurite was taken as the point of incidence from the cell soma. The data was assessed by a single, blinded 
researcher, and the experiment was performed in three independent instances from three separate control and 
cKO cerebella. Proliferation data in Fig. 3d was quantified by counting the number of pH3B+ cells in 100um x 
100um squares from every 30th section (10um thick sections) of three tumours of each genotype (each from a 
separate animal), followed by averaging. The same method was used to obtain data in Fig. 4d. Ki67+, Sox2+ and 
TuJ1+ CPCs quantified in Figs. 5d,e, 6d,e were counted in the same manner as the GCP data described above. 
Fluorescent images were captured using Nikon Eclipse 80i with Nikon Y-QT Hamamatsu C4742-95 camera. 
Acquired fluorescent images from cell culture experiments were subjected to an identical intensity threshold, 
as judged by the investigator, in ImageJ (separately for each antigen) before counting positive cells. The experi-
menter was blinded for the IHC/ICC quantification in (Figs. 1, 3 and 4) and data quantification in the cell culture 
experiments (Figs. 2 and 5) was done and repeated by another researcher in double-blind fashion where neither 
of the researchers was aware of the culture conditions or group identity.
Image processing. Images were processed using Adobe Photoshop CC 2017 and figures assembled in Adobe 
Illustrator CC 2017.
Statistics. Statistical analysis was carried out and graphs generated using GraphPad Prism 5®. Most data were 
analysed using a Student’s t-test with the exception of the Kaplan-Meier survival analysis which used the log-rank 
test or Cox regression analysis. P < 0.05 was considered significant.
Transcriptomic analyses from human data. Read counts for AHR and AHRR expression were produced by align-
ing paired end RNA-seq (~90 M read/sample Illumina HiSeq 2500) reads to HG19 genome using STAR-align52. 
Read counts were produced using HT-SEQ-count. DESeq 2 (R/Bioconductor) was used to normalise reads 
to library size and variance stabilised data (VSD) was generated using the vsd function. Statistical testing for 
differential expression across groups was performed using an ANOVA test. Affymetrix expression data were 
obtained from previously reported series through GEO accession numbers GSE103278, GSE1299253, GSE3741854, 
GSE4924355 and published previously56. All data were MAS5.0 normalized and analysed using the genomics 
analysis and visualization platform R2 (http://r2.amc.nl). For survival analyses the Kaplan scanning tool in R2 
was used that identifies the optimal cut off in expression in a dataset that results in the lowest log rank p value in 
overall survival analyses between the subset with high expression and the subset with low expression of the gene 
of interest. Log rank p-value is corrected for multiple testing using the Bon Ferroni method.
Ethical approval. All animal experiments were approved by the King’s College London Animal Welfare 
and Ethical Review Board (AWERB) and the UK Home Office (Project licence P8DC5B496), in accordance with 
the relevant guidelines and practises. For studies using human tissue and clinical information, all methods were 
carried out in accordance with relevant guidelines and regulations, all experimental protocols were approved 
by a named institutional and/or licensing committee and informed consent was obtained from all participants 
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or their legal guardians. For the Newcastle cohort, tumour samples were provided by the UK CCLG as part of 
CCLG-approved biological study BS-2007–04. Tumour investigations were done with approval from Newcastle 
North Tyneside Research Ethics Committee (study reference 07/Q0905/71). For the Toronto cohort, medul-
loblastoma samples were collected at diagnosis after obtaining informed consent from subjects as part of the 
Medulloblastoma Advanced Genomics International Consortium. Approval was obtained from institutional 
research ethics boards at all contributing institutions as outlined by Cavalli et al.6. For the Heidelberg cohort, all 
tumors were collected after receiving informed consent according to ICGC guidelines and approved by the insti-
tutional review board of contributing centers.
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